Worthy of mention here is the fact that two of the above-mentioned malignancies not undergoing a direct cytopathic effect by IFN-α treatment, Hairy cell leukemia and chronic myelogenous leukemia are two of the approved indications for IFN-α 2 in the United States, the first being approved for both IFN-α2a (Hoffman-La Roche©) and –α2b (Schering-Plough©) and having the distinction of being the first approved indication for both in 1986 whereas chronic myelogenous leukemia (CML) is an approved indication only of IFN-α2a. Here, IFNA1 is linked to hairy cell leukemia.